117 related articles for article (PubMed ID: 38006237)
1. Ticagrelor enhances the cardioprotective effects of ischemic preconditioning in stable patients undergoing percutaneous coronary intervention: the TAPER-S randomized study.
D'Amario D; Galli M; Restivo A; Canonico F; Vergallo R; Migliaro S; Trani C; Burzotta F; Aurigemma C; Laborante R; Romagnoli E; Francese F; Ceccarelli I; Borovac JA; Angiolillo DJ; Tavazzi B; Leone AM; Crea F; Patti G; Porto I
Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):190-200. PubMed ID: 38006237
[TBL] [Abstract][Full Text] [Related]
2. Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial.
D'Amario D; Restivo A; Leone AM; Vergallo R; Migliaro S; Canonico F; Galli M; Trani C; Burzotta F; Aurigemma C; Niccoli G; Buffon A; Montone RA; Flex A; Franceschi F; Tinelli G; Limbruno U; Francese F; Ceccarelli I; Borovac JA; Porto I; Crea F
Trials; 2020 Feb; 21(1):192. PubMed ID: 32066489
[TBL] [Abstract][Full Text] [Related]
3. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
4. Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.
Khan JN; Greenwood JP; Nazir SA; Lai FY; Dalby M; Curzen N; Hetherington S; Kelly DJ; Blackman D; Peebles C; Wong J; Flather M; Swanton H; Gershlick AH; McCann GP
J Am Heart Assoc; 2016 May; 5(6):. PubMed ID: 27247336
[TBL] [Abstract][Full Text] [Related]
5. P2Y
Ortega-Paz L; Bor W; Franchi F; van den Broek WWA; Rollini F; Giordano S; Galli M; Been L; Ghanem G; Shalhoub A; Garabedian H; Al Saleh T; Uzunoglu E; Zhou X; Rivas A; Pineda AM; Suryadevara S; Soffer D; Mahowald MK; Choi CY; Zenni MM; Phoenix F; Ajjan RA; Ten Berg JM; Angiolillo DJ
JACC Cardiovasc Interv; 2024 Jun; 17(11):1356-1370. PubMed ID: 38597172
[TBL] [Abstract][Full Text] [Related]
6. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
[TBL] [Abstract][Full Text] [Related]
7. Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome.
Manzo-Silberman S; Guedeney P; Cayla G; Beygui F; Rangé G; Motovska Z; Procopi N; Kerneis M; Zeitouni M; El Kasty M; Teiger E; Filippi E; Coste P; Huchet F; Cottin Y; Karasek J; Arnould MA; Braik N; Barthelemy O; Portal JJ; Vicaut E; Montalescot G; Silvain J;
JACC Cardiovasc Interv; 2024 Jun; 17(12):1413-1421. PubMed ID: 38842993
[TBL] [Abstract][Full Text] [Related]
8. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
9. Translation of experimental cardioprotective capability of P2Y
Hjortbak MV; Olesen KKW; Seefeldt JM; Lassen TR; Jensen RV; Perkins A; Dodd M; Clayton T; Yellon D; Hausenloy DJ; Bøtker HE;
Basic Res Cardiol; 2021 May; 116(1):36. PubMed ID: 34037861
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.
Piqueras-Flores J; Jurado-Román A; López-Lluva MT; Sánchez-Pérez I; Abellán-Huerta J; Lozano-Ruiz Poveda F
J Cardiovasc Pharmacol; 2019 Jan; 73(1):56-59. PubMed ID: 30383607
[TBL] [Abstract][Full Text] [Related]
11. Impact of Ticagrelor Versus Clopidogrel on Coronary Microvascular Function After Non-ST-Segment-Elevation Acute Coronary Syndrome.
Xu J; Lo S; Mussap CJ; French JK; Rajaratnam R; Kadappu K; Premawardhana U; Nguyen P; Juergens CP; Leung DY
Circ Cardiovasc Interv; 2022 Apr; 15(4):e011419. PubMed ID: 35369712
[TBL] [Abstract][Full Text] [Related]
12. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
[TBL] [Abstract][Full Text] [Related]
14. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
Wang Z; Zhou DY; Su Y; Si LY; Xu Q
BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
[TBL] [Abstract][Full Text] [Related]
16. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
Abtan J; Ducrocq G; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL
Circ Cardiovasc Interv; 2019 Mar; 12(3):e007445. PubMed ID: 30871355
[TBL] [Abstract][Full Text] [Related]
17. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
Zanchin T; Temperli F; Karagiannis A; Zanchin C; Räsänen M; Koskinas KC; Stortecky S; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Billinger M; Heg D; Pilgrim T; Valgimigli M; Windecker S; Räber L
Circ Cardiovasc Interv; 2018 May; 11(5):e006132. PubMed ID: 29748219
[TBL] [Abstract][Full Text] [Related]
18. Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Aytekin A; Ndrepepa G; Neumann FJ; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Lahu S; Richardt G; Witzenbichler B; Sibbing D; Cassese S; Angiolillo DJ; Valina C; Kufner S; Liebetrau C; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Wustrow I; Joner M; Trenk D; Fusaro M; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
Circulation; 2020 Dec; 142(24):2329-2337. PubMed ID: 33115278
[TBL] [Abstract][Full Text] [Related]
19. Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y
Xi Z; Wang Y; Lu Q; Qiu H; Gao Y; Gao A; Gao R
Thromb Res; 2023 Aug; 228():85-93. PubMed ID: 37301117
[TBL] [Abstract][Full Text] [Related]
20. Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial.
Park DW; Kwon O; Jang JS; Yun SC; Park H; Kang DY; Ahn JM; Lee PH; Lee SW; Park SW; Choi SW; Lee SG; Yoon HJ; Ahn T; Kim MH; Nah DY; Lee SY; Chae JK; Park SJ;
Circulation; 2019 Dec; 140(23):1865-1877. PubMed ID: 31553203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]